Thursday, October 4, 2012

Meridian Bioscience Inc (VIVO) 2012 Review

Meridian Bioscience Inc. makes diagnostic test kits, purified reagents as well as biopharmaceutical technologies to hospitals, laboratories, veterinary and physician offices, diagnostic manufacturers and biotech companies.  VIVO has grown dividends and profits at a 15-20% pace over the last ten years earning a 20-30% return on equity.  The dividend growth rate has slowed recently but should resume growing at the same rate as profits in the future.  The company’s prospects appear bright as a result of:

(1)   impressive growth in the company’s illumigene molecular test platforms,

(2)   aggressive cost control effort,

(3)   strong pipeline of new products.

Negatives:

(1)   tough economic environment discourages doctor visits,

(2) its large foreign exposure subjects it to currency risks.

            VIVO is rated B++ by Value Line, has no debt and its stock yields 4.2%.


                Stock      Dividend         Payout      # Increases 
               Yield      Growth Rate     Ratio       Since 2002

VIVO        4.2%           5%              80%             9
Ind Ave      1.2              10*             32               NA

                Debt/                      EPS Down       Net        Value Line
              Equity         ROE      Since 2002      Margin       Rating

VIVO       0%             30%            1                21%           B++
Ind Ave    19               18             NA                5              NA

*few companies in VIVO industry pay a dividend

    Chart

            Note: VIVO stock made limited progress off its March 2009 low.  While it has surpassed the downtrend off its April 2008 high (straight red line), it has not successfully penetrated the November 2008 trading high (green line).  Long term, the stock is in a trading range (blue lines).  Intermediate term, it is in a trading range (purple lines).  The wiggly red line is the 50 day moving average.  The High Yield Portfolio does not own a position in VIVO.  The upper boundary of its Buy Value Range is $15; the lower boundary of its Sell Half Range is $31.
           


10/12

No comments:

Post a Comment